This article is more than 5 years old. Information may no longer be current.

VALOR II: Thoracic stent graft system shows durability at 5 years

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A stent graft system used to repair thoracic aortic aneurysms was safe and effective at 5 years, with a high rate of freedom from aneurysm-related mortality and low rate of rupture, according to results from the VALOR II study.

The results “confirm that [thoracic endovascular aortic repair] should be the primary treatment option for patients with isolated aneurysms of the descending thoracic aorta,” Mark F. Conrad, MD, MMSC, who presented the findings at the 42nd annual meeting of the New England Society for Vascular Surgery, told Cardiology Today’s Intervention.

In the single-arm, prospective VALOR II study, 160 patients were treated with a thoracic aortic stent graft system (Valiant, Medtronic) for thoracic endovascular aortic repair of aneurysms located in the descending thoracic aorta, according to a press release from Medtronic.

At 5 years, 94.8% of patients were free from aneurysm-related mortality and the rupture rate was 1.3%, according to the release.

In addition, 6.9% of patients required a secondary procedure, 0.6% required open surgery and 89.3% had a decrease in or no change in aneurysm size. No patients experienced migration or loss of integrity, according to the release.

The findings also indicated that “late type I endoleaks do occur and need to be treated to prevent late aneurysm-related death,” Conrad, director of clinical research and assistant program director in the division of vascular and endovascular surgery at Massachusetts General Hospital, told Cardiology Today’s Intervention. “This makes long-term surveillance mandatory in those patients.” ˗ by Erik Swain

Reference:

Conrad MF, et al. Scientific Session I. Presented at: New England Society for Vascular Surgery Annual Meeting; Oct. 2-4, 2015; Newport, R.I.

For more information:

Mark F. Conrad, MD, MMSC, can be reached at Massachusetts General Hospital,

55 Fruit St., Wac 458, Boston, MA 02114; email: mconrad@partners.org.

Disclosure: The study was sponsored by Medtronic. Conrad reports consulting for Medtronic but was not paid for the presentation or manuscript preparation.